

Behzad Hajarizadeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8240163/publications.pdf>

Version: 2024-02-01

145
papers

8,797
citations

71061

41
h-index

45285

90
g-index

146
all docs

146
docs citations

146
times ranked

9133
citing authors

#	ARTICLE	IF	CITATIONS
1	High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH Study. <i>Hepatology Communications</i> , 2022, 6, 496-512.	2.0	10
2	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. <i>Hepatology</i> , 2022, 76, 139-154.	3.6	42
3	Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. <i>Journal of Infectious Diseases</i> , 2022, 226, 1005-1021.	1.9	24
4	Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia. <i>BMC Public Health</i> , 2022, 22, 536.	1.2	1
5	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The STOp-C Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1809-1819.	2.9	11
6	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	3.7	237
7	Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 426-445.	3.7	50
8	Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH cohort. <i>Journal of Viral Hepatitis</i> , 2022, 29, 661-676.	1.0	7
9	Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. <i>Lancet HIV</i> , 2022, 9, e414-e427.	2.1	23
10	Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. <i>BMJ Open</i> , 2022, 12, e058757.	0.8	1
11	Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia. <i>Viruses</i> , 2022, 14, 1496.	1.5	8
12	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. <i>Viruses</i> , 2022, 14, 1555.	1.5	7
13	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1392-1400.	2.9	26
14	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 1664-1676.	1.7	9
15	Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingertick Capillary Dried Blood Spot and Venepuncture-Collected Samples. <i>Journal of Infectious Diseases</i> , 2021, 223, 818-826.	1.9	7
16	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. <i>Journal of Hepatology</i> , 2021, 74, 293-302.	1.8	27
17	HCV Elimination in Australia. , 2021, , 213-227.		0
18	Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival. <i>Journal of Viral Hepatitis</i> , 2021, 28, 710-718.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 6168-6176.	0.7	12
20	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 533-546.	3.7	48
21	Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1340-1354.	1.0	26
22	Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. <i>International Journal of Drug Policy</i> , 2021, 96, 103422.	1.6	15
23	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons. <i>Hepatology</i> , 2021, 74, 2366-2379.	3.6	9
24	Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. <i>Medical Journal of Australia</i> , 2021, 215, 332-333.	0.8	8
25	Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications. <i>PLoS ONE</i> , 2021, 16, e0257369.	1.1	13
26	All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	5
27	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e107-e118.	2.9	39
28	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. <i>International Journal of Drug Policy</i> , 2021, 96, 103469.	1.6	7
29	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2369-2376.	2.9	19
30	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 281-293.	1.0	39
31	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. <i>Clinical Infectious Diseases</i> , 2020, 71, e115-e124.	2.9	53
32	Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 34-52.	1.9	22
33	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 643-657.	1.8	103
34	Hepatitis C elimination in Australia: progress and challenges. <i>Medical Journal of Australia</i> , 2020, 212, 362-363.	0.8	9
35	Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. <i>Sexual Health</i> , 2020, 17, 223.	0.4	8
36	Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 2043-2049.	1.9	16

#	ARTICLE	IF	CITATIONS
37	Addressing cultural diversity: the hepatitis B clinical specialist perspective. <i>Ethnicity and Health</i> , 2019, 24, 816-828.	1.5	8
38	An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. <i>International Journal of Drug Policy</i> , 2019, 72, 99-105.	1.6	27
39	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. <i>International Journal of Drug Policy</i> , 2019, 72, 1-10.	1.6	40
40	SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression. <i>Journal of Hepatology</i> , 2019, 70, e733.	1.8	5
41	Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran. <i>International Journal of Drug Policy</i> , 2019, 73, 129-134.	1.6	18
42	Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1423-1430.	1.0	12
43	Cure and Control: What Will It Take to Eliminate HCV?. <i>Topics in Medicinal Chemistry</i> , 2019, , 447-490.	0.4	2
44	Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. <i>Journal of Hepatology</i> , 2019, 71, 281-288.	1.8	76
45	Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 969-979.	1.0	25
46	Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 83-92.	1.0	58
47	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. <i>Clinical Infectious Diseases</i> , 2018, 66, 20-28.	2.9	21
48	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. <i>International Journal of Drug Policy</i> , 2018, 54, 18-25.	1.6	46
49	Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 640-648.	1.0	68
50	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 153-161.	3.7	231
51	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
52	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. <i>Journal of Infectious Diseases</i> , 2018, 217, 1889-1896.	1.9	88
53	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. <i>Journal of Medical Virology</i> , 2018, 90, 120-130.	2.5	6
54	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 473-481.	1.0	19

#	ARTICLE	IF	CITATIONS
55	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. <i>Journal of Hepatology</i> , 2018, 68, 393-401.	1.8	58
56	Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 754-767.	3.7	174
57	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	1.6	58
58	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2018, 61, 23-30.	1.6	57
59	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	1.6	22
60	Management of acute HCV infection in the era of direct-acting antiviral therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 412-424.	8.2	62
61	Elimination of Hepatitis C Virus in Australia. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 269-279.	1.9	65
62	Evaluation of the Xpert fingerstick HCV viral load assay. <i>Journal of Hepatology</i> , 2018, 68, S167.	1.8	0
63	Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The STOp-C study. <i>Journal of Hepatology</i> , 2018, 68, S187-S188.	1.8	2
64	Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 621-627.	1.2	17
65	Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	29
66	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, 215.	1.3	22
67	Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake. <i>Journal of Hepatology</i> , 2018, 68, S153.	1.8	4
68	Editorial: Observations on the launch of new drugs for hepatitis C. <i>Australian Prescriber</i> , 2018, 41, 4-5.	0.5	10
69	Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 229-236.	1.4	61
70	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
71	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-ep study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 733-741.	1.0	61
72	HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. <i>Current HIV/AIDS Reports</i> , 2017, 14, 110-121.	1.1	46

#	ARTICLE	IF	CITATIONS
73	Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 514-520.	3.7	123
74	Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study. <i>Journal of Hepatology</i> , 2017, 66, S513.	1.8	2
75	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. <i>Journal of Clinical Virology</i> , 2017, 92, 32-38.	1.6	32
76	No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. <i>Journal of Hepatology</i> , 2017, 66, S12.	1.8	8
77	Direct-acting antiviral agents for HCV infection affecting people who inject drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 641-651.	8.2	127
78	Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. <i>International Journal of Drug Policy</i> , 2017, 47, 34-46.	1.6	158
79	Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study. <i>Journal of Hepatology</i> , 2017, 66, S274.	1.8	3
80	Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools. <i>Journal of Hepatology</i> , 2017, 66, S710.	1.8	1
81	The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments. <i>Journal of Hepatology</i> , 2017, 66, S291-S292.	1.8	8
82	Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study. <i>Journal of Hepatology</i> , 2017, 66, S488.	1.8	0
83	A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit. <i>Journal of Hepatology</i> , 2017, 66, S495.	1.8	0
84	Field evaluation of Xpert [®] HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples. <i>Journal of Hepatology</i> , 2017, 66, S709.	1.8	0
85	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 177-186.	1.6	13
86	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 230-238.	1.6	28
87	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. <i>Journal of Hepatology</i> , 2017, 67, 1204-1212.	1.8	390
88	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. <i>BMC Infectious Diseases</i> , 2017, 17, 420.	1.3	6
89	Higher incidence of <sc>HCV</sc> in females compared to males who inject drugs: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 117-127.	1.0	51
90	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). <i>Hepatology Communications</i> , 2017, 1, 736-747.	2.0	8

#	ARTICLE	IF	CITATIONS
91	O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued. <i>Journal of Virus Eradication</i> , 2017, 3, 5.	0.3	3
92	More than a virus: a qualitative study of the social implications of hepatitis B infection in China. <i>International Journal for Equity in Health</i> , 2017, 16, 137.	1.5	38
93	Estimating the Prevalence of Hepatitis B Virus Infection and Exposure Among General Population in Iran. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	12
94	Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	12
95	Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. <i>Hepatitis Monthly</i> , 2016, 16, e40959.	0.1	63
96	Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. <i>Journal of Hepatology</i> , 2016, 65, 879-887.	1.8	29
97	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. <i>Liver International</i> , 2016, 36, 1774-1782.	1.9	8
98	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 317-327.	3.7	80
99	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000â€“2014). <i>Journal of Hepatology</i> , 2016, 65, 1086-1093.	1.8	36
100	Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting, 2005â€“2014: The Hits-P Study. <i>Journal of Hepatology</i> , 2016, 64, S614.	1.8	0
101	Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse. <i>Journal of Hepatology</i> , 2016, 64, S625-S626.	1.8	0
102	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. <i>Virology Journal</i> , 2016, 13, 32.	1.4	10
103	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2016, 16, 241.	1.3	5
104	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2016, 37, 252-258.	1.0	13
105	Hepatitis B-Related Concerns and Anxieties Among People With Chronic Hepatitis B in Australia. <i>Hepatitis Monthly</i> , 2016, 16, e35566.	0.1	14
106	Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. <i>Hepatitis Monthly</i> , 2016, 16, e37234.	0.1	44
107	Strategies to manage hepatitis C virus infection disease burden â€“ volume 3. <i>Journal of Viral Hepatitis</i> , 2015, 22, 42-65.	1.0	62
108	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm â€“ volume 3. <i>Journal of Viral Hepatitis</i> , 2015, 22, 21-41.	1.0	61

#	ARTICLE	IF	CITATIONS
109	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 4-20.	1.0	109
110	Hepatitis B knowledge and associated factors among people with chronic hepatitis B. Australian and New Zealand Journal of Public Health, 2015, 39, 563-568.	0.8	41
111	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. PLoS ONE, 2015, 10, e0122232.	1.1	41
112	P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study. Journal of Hepatology, 2015, 62, S657.	1.8	0
113	Interferon Î» 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. Journal of Molecular Diagnostics, 2015, 17, 583-589.	1.2	3
114	Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfectionâ€™the InC³ Study. Journal of Infectious Diseases, 2015, 212, 1407-1419.	1.9	82
115	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC³ study. Journal of Viral Hepatitis, 2015, 22, 708-717.	1.0	13
116	Patients' perspectives on the delivery of hepatitis B management and care. Australian Family Physician, 2015, 44, 346.	0.5	2
117	Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?. Liver International, 2014, 34, 964-964.	1.9	4
118	Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?. Hepatology, 2014, 59, 1650-1651.	3.6	5
119	The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology, 2014, 59, 109-120.	3.6	320
120	Letter: the rs12979860 and ss469415590 polymorphisms of FNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2014, 39, 343-343.	1.9	11
121	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. Journal of Clinical Virology, 2014, 61, 430-434.	1.6	8
122	Dynamics of HCV RNA levels during acute hepatitis C virus infection. Journal of Medical Virology, 2014, 86, 1722-1729.	2.5	26
123	Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 553-562.	8.2	833
124	1157 EARLY HCV RNA DYNAMICS AND FACTORS ASSOCIATED WITH HIGH EARLY HCV RNA LEVEL DURING ACUTE HCV INFECTION. Journal of Hepatology, 2013, 58, S470-S471.	1.8	2
125	461 SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION IS ASSOCIATED WITH FEMALE SEX, IL28B GENOTYPE AND HCV GENOTYPE 1 INFECTION. Journal of Hepatology, 2013, 58, S189.	1.8	1
126	Challenges in managing patients in Australia with chronic hepatitis B: the General Practitionersâ€™ perspective. Australian and New Zealand Journal of Public Health, 2013, 37, 405-410.	0.8	22

#	ARTICLE	IF	CITATIONS
127	Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia. <i>Sexual Health</i> , 2012, 9, 131.	0.4	19
128	Case definitions for acute hepatitis C virus infection: A systematic review. <i>Journal of Hepatology</i> , 2012, 57, 1349-1360.	1.8	46
129	Managing chronic hepatitis B - the role of the GP. <i>Australian Family Physician</i> , 2012, 41, 893-8.	0.5	7
130	Managing chronic hepatitis B: A qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia. <i>BMC Research Notes</i> , 2011, 4, 45.	0.6	57
131	Trends and geographical inequalities of the main health indicators for rural Iran. <i>Health Policy and Planning</i> , 2009, 24, 229-237.	1.0	27
132	Sexual Function: A Comparison Between Male Renal Transplant Recipients and Hemodialysis Patients. <i>Journal of Sexual Medicine</i> , 2009, 6, 142-148.	0.3	33
133	Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. <i>Liver International</i> , 2009, 29, 159-163.	1.9	70
134	PIN15 COMPARING COST-EFFECTIVENESS OF THE THREE- VERSUS TWO-DOSE VACCINATION PROTOCOL AGAINST HEPATITIS B IN ADOLESCENTS. <i>Value in Health</i> , 2009, 12, A112.	0.1	0
135	PIN27 COST ANALYSIS OF THE MASS VACCINATION CAMPAIGN AGAINST HEPATITIS B IN ADOLESCENTS IN IRAN. <i>Value in Health</i> , 2009, 12, A114.	0.1	0
136	Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. <i>Nephrology</i> , 2008, 13, 376-379.	0.7	17
137	Temporal variations of health indicators in Iran comparing with other Eastern Mediterranean Region countries in the last two decades. <i>Journal of Public Health</i> , 2008, 30, 499-504.	1.0	21
138	Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: a multicenter study. <i>Archives of Iranian Medicine</i> , 2006, 9, 319-23.	0.2	77
139	Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with "illegal social behaviour". <i>Sexually Transmitted Infections</i> , 2005, 81, 185-185.	0.8	31
140	Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease. <i>BMC Endocrine Disorders</i> , 2004, 4, 4.	0.9	18
141	Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 836-840.	1.4	35
142	Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. <i>Nephrology</i> , 2003, 8, 256-260.	0.7	44
143	Efficacy and safety of lamivudine for treatment of chronic hepatitis B in renal allograft recipients. <i>Transplantation Proceedings</i> , 2003, 35, 2687-2688.	0.3	4
144	Is preemptive renal transplantation preferred?. <i>Transplantation Proceedings</i> , 2003, 35, 2598-2601.	0.3	9

#	ARTICLE	IF	CITATIONS
145	Patient and graft outcome after living donor renal transplantation in Iran: more than 15-year follow-up. Transplantation Proceedings, 2003, 35, 2605-2606.	0.3	4